<DOC>
	<DOCNO>NCT00298662</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability combination interferon beta 1-b ( Betaseron® ) tacrolimus ( Prograf® ) patient suffer multiple sclerosis ( MS ) fail treatment currently approve drug MS Prograf immunosuppressant weaken immune reaction responsible protect organism infection . It currently available market patient receive organ transplant , prevent rejection . Because effect immune system , theoretically , Prograf exert significant effect MS . It try small number MS patient low dose one use organ transplant , however result study allow draw definite conclusion safety efficacy MS. Betaseron approve Canada reduction frequency relapse patient relapsing-remitting MS slow progression reduction frequency relapse patient secondary-progressive MS . The combination Betaseron Prograf may result additive effect increase action drug . However , combination two drug never study . The aim study see well combination Betaseron Prograf tolerate patient MS . The side effect treatment , , follow . In addition , efficacy combination evaluate .</brief_summary>
	<brief_title>Combination Therapy Betaseron-Prograf Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>relapsingremitting secondaryprogressive multiple sclerosis patient fail treatment approve immunomodulator drug ( experience high annual relapse rate experinced progression EDSS scale ) Expanded Disability Status Scale ( EDSS ) score less 7.0 follow condition : diabetes mellitus , uncontrolled hypertension , active infection viral disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Betaseron-Prograf</keyword>
	<keyword>patient Multiple Sclerosis</keyword>
	<keyword>Secondary Progressive type</keyword>
	<keyword>Relapsing-Remitting type</keyword>
</DOC>